Global Preeclampsia Laboratory Testing Market 2024-2028
The preeclampsia laboratory testing market is forecasted to grow by USD 855.3 mn during 2023-2028, accelerating at a CAGR of 8.09% during the forecast period. The report on the preeclampsia laboratory testing market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by market expansion in emerging economies, increasing incidence of preterm births, and rising number of gynecology clinics.
Technavio's preeclampsia laboratory testing market is segmented as below:
By Product Type
By Test
- Blood test
- Urine test
- Others
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
This study identifies the growing need for companion diagnostics as one of the prime reasons driving the preeclampsia laboratory testing market growth during the next few years. Also, growing awareness of mother and fetal screening and monitoring procedures and implementation of organic and inorganic strategies by market players will lead to sizable demand in the market.
The report on the preeclampsia laboratory testing market covers the following areas:
- Preeclampsia laboratory testing market sizing
- Preeclampsia laboratory testing market forecast
- Preeclampsia laboratory testing market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading preeclampsia laboratory testing market vendors that include Abbott Laboratories, ACON Laboratories Inc., Avecon Healthcare Pvt. Ltd., Bio Rad Laboratories Inc., BioCheck Inc., bioMerieux SA, Biora Therapeutics Inc., Cardinal Health Inc., Diabetomics Inc., F. Hoffmann La Roche Ltd., GestVision Inc., Lifeassay Diagnostics Pty Ltd., MedGyn Products Inc., Metabolomic Diagnostics, MOMM Diagnostics, Perkin Elmer Inc., Quidelortho Corp., Sera Prognostics Inc., Siemens AG, and Thermo Fisher Scientific Inc.. Also, the preeclampsia laboratory testing market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.